Cytoo appoints CEO for new US unit
This article was originally published in Clinica
French developer of high-content cell analysis technologies Cytoo has appointed William Sharp president and CEO of its newly-established US subsidiary. Mr Sharp, who was most recently president and CEO of stem cell technologies company ArunA Biomedical, brings 30 years' experience of marketing life science products and diagnostics to Cytoo's Framingham, Massachusetts-based division. He will oversee opportunities for the company's expansion in North America, and seek to create co-distribution and partnership agreements with leading players in cell-based assays for the drug discovery market. Market data indicate that worldwide sales of cell-based assays reached $1.7bn in 2007, according to Grenoble-headquartered Cytoo.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.